Investor Presentation Full Year 2021
37
Investor presentation
Full year 2021
Novo NordiskⓇ
Global diabetes prevalence is increasing with 700 million people.
expected to have diabetes by 2045
The number of people with diabetes is expected to
increase 51% by 2045
Of the 463 million, 34.6 million¹ people are currently treated with
Novo Nordisk diabetes products
Million
800
600
400
200
0
+51%
579
J
463
700
2019
2030
2045
EMEA
Region China
ROW
North America
Source: International Diabetes Federation: Diabetes Atlas 1st Edition 2000 and Diabetes Atlas 9th Edition 2019
EMEA: Europe, Middle East, Africa; RoW: Asia Pacific, Latin America
3.9 mio treated with GLP-1
3.7 mio treated with
new-generation insulin
13.0 mio treated with
modern insulin
12.3 mio treated with
human insulins
1 In addition to the above-mentioned product classes, oral anti-diabetics constitutes the remainder of people treated with Novo
Nordisk products; Estimated number for full-year 2021. Source: Novo Nordisk Annual Report 2021View entire presentation